Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?

Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.

So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings.

Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving growth. The next-generation drugs in oncology and obesity are the next potential wave of growth, with even more exciting treatments following them.

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Regeneron shares have recently crossed over the $1,000 price point. The company has achieved significant growth and there could more to come.

Regeneron's Q2 2024 revenue grew 12% year-over-year, reaching $3.55 billion. Dupixent's global net sales increased by 27% to $3.56 billion, driving overall revenue growth. Eylea HD mitigated market share losses by earning $304 million and stabilizing the Eylea franchise.

Over the past month we have observed some very interesting activity across the market's more defensive sectors, considerable outperformance. Below we can see just how significantly the Utilities ( XLU ), Healthcare ( XLV ), Energy ( XLE ) and Real Estate ( XLRE ) sector ETF have outperformed the S&P 500 (in orange).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Evan Seigerman - BMO Capital Markets Brian Abrahams - RBC Capital Markets Cory Kasimov - Evercore ISI Christopher Raymond - Piper Sandler Katherine Wang - Jefferies Chris Schott - JPMorgan Tim Anderson - Wolfe Research David Risinger - Leerink Partners Salveen Richter - Goldman Sachs Carter Gould - Barclays Mohit Bansal - Wells Fargo Operator Welcome to the Regeneron Pharmaceuticals Second Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.

Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs.